GlassScriptPhysician profile
Jacquelyn Nestor
NPI 1841730959
$5,926.24
in general payments reported to CMS, 2019-2025
37 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,376 · 2022: $1,229 · 2023: $2,003 · 2024: $1,212 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,312 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,312.43 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,051.59 | 2021-2025 | |
| Novo Nordisk INC | $902.18 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $639.63 | 2021-2024 | Jardiance, Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $320.53 | 2021-2024 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $294.23 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $291.22 | 2021-2023 | Belsomra, Vaxelis, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $265.78 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.76 | 2022-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.15 | 2021-2024 | Jardiance |
| Abbott Laboratories | $224.73 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $190.98 | 2021-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $155.50 | 2023-2024 | |
| Glaxosmithkline, LLC. | $132.62 | 2022-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Mannkind Corporation | $97.02 | 2021-2024 | Afrezza |
| Phathom Pharmaceuticals, INC. | $81.65 | 2024 | Voquezna |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Nestor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.